Incyte (INCY) Non-Current Assets (2010 - 2026)
Incyte's (INCY) quarterly Non-Current Assets came in at $1.8 billion in Q2 2026, down 15.23% YoY from $2.2 billion in Q2 2025, and little changed on a QoQ basis from $1.9 billion in Q1 2026.
Incyte (INCY) Non-Current Assets (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Non-Current Assets data on file, last reported at $1.8 billion in Q2 2026.
- Quarterly Non-Current Assets fell 15.23% year-over-year to $1.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.7 billion (down 12.93% YoY) and the FY2025 annual result came in at $1.9 billion, down 12.3% from the prior year.
- Non-Current Assets was little changed at $1.8 billion in Q2 2026, from $1.9 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $2.3 billion in Q1 2024 to a low of $1.7 billion in Q3 2022.
- A 5-year average of $2.0 billion and a median of $2.0 billion in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 45.78% — and 2026, when it declined 17.27%.
- Tracing INCY's Non-Current Assets over 5 years: stood at $1.7 billion in 2022, then grew by 22.23% to $2.1 billion in 2023, then rose by 3.21% to $2.2 billion in 2024, then declined by 12.3% to $1.9 billion in 2025, then declined by 4.55% to $1.8 billion in 2026.
- The last three Non-Current Assets figures came in at $1.8 billion (Q2 2026), $1.9 billion (Q1 2026), and $1.9 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 1.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.85 Bn |
| Mar 31, 2026 | 1.85 Bn |
| Dec 31, 2025 | 1.93 Bn |
| Sep 30, 2025 | 2.05 Bn |
| Jun 30, 2025 | 2.18 Bn |
| Mar 31, 2025 | 2.24 Bn |
| Dec 31, 2024 | 2.21 Bn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 2.09 Bn |
| Mar 31, 2024 | 2.29 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 1.99 Bn |
| Jun 30, 2023 | 1.94 Bn |
| Mar 31, 2023 | 1.83 Bn |
| Dec 31, 2022 | 1.75 Bn |
| Sep 30, 2022 | 1.69 Bn |
| Jun 30, 2022 | 1.69 Bn |
| Mar 31, 2022 | 1.77 Bn |
| Dec 31, 2021 | 1.81 Bn |
| Sep 30, 2021 | 1.28 Bn |